Cargando…
Evaluation of Pharmacokinetics and Pharmacodynamics of Deferasirox in Pediatric Patients
Background: Deferasirox (DFX) is commonly used to reduce the chronic iron overload (IO) in pediatric patients. However, the drug is characterized by a large pharmacokinetic variability and approximately 10% of patients may discontinue the treatment due to toxicities. Therefore, the present retrospec...
Autores principales: | Galeotti, Laura, Ceccherini, Francesco, Fucile, Carmen, Marini, Valeria, Di Paolo, Antonello, Maximova, Natalia, Mattioli, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8401444/ https://www.ncbi.nlm.nih.gov/pubmed/34452199 http://dx.doi.org/10.3390/pharmaceutics13081238 |
Ejemplares similares
-
What is known about deferasirox chelation therapy in pediatric HSCT recipients: two case reports of metabolic acidosis
por: Fucile, Carmen, et al.
Publicado: (2018) -
Safety and tolerability of deferasirox in pediatric hematopoietic stem cell transplant recipients: one facility's five years’ experience of chelation treatment
por: Maximova, Natalia, et al.
Publicado: (2017) -
Population Pharmacokinetics of Intravenous Acyclovir in Oncologic Pediatric Patients
por: Maximova, Natalia, et al.
Publicado: (2022) -
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019) -
Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
por: Flores-Pérez, Carmen, et al.
Publicado: (2023)